A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Untreated Follicular Lymphoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,018 (planned)
- Started
- Aug 7, 2024
- Main results expected
- Nov 26, 2031
- Fully finished
- Nov 26, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
SRI Primary: Incidence, nature and severity of AEs and SAEs. Incidence and nature of study drug discontinuations, dose reductions, and dose delays due to AEs
Measured over: Up to 10 years
SRI Primary: Determination of the recommended Phase III dose (RP3D)
Measured over: Up to 1 year
Phase 3 Dual Primary: To demonstrate the superiority of Surovatamig plus rituximab compared to Investigator's choice of SoC chemoimmunotherapy
Measured over: Up to 10 years
Phase 3 Dual Primary: To demonstrate the superiority of Surovatamig plus rituximab compared to Investigator's choice of SoC chemoimmunotherapy
Measured over: Up to 10 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06549595 · record last updated 2026-10-21 · checked 2026-11-09 15:47 UTC